MeSH term
Frequency | Condition_Probility | Aged | 77 | 0.0 |
Cohort Studies | 6 | 0.0 |
Humans | 295 | 0.0 |
Adolescent | 42 | 0.0 |
Age Factors | 12 | 0.0 |
Child | 32 | 0.0 |
Child, Preschool | 21 | 0.0 |
Female | 178 | 0.0 |
Hematocrit | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Male | 172 | 0.0 |
Nigeria | 2 | 3.0 |
Reference Values | 21 | 0.0 |
Analysis of Variance | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 121 | 0.0 |
Adult | 141 | 0.0 |
Disease Progression | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Middle Aged | 115 | 0.0 |
Retrospective Studies | 8 | 0.0 |
Animals | 51 | 0.0 |
Comparative Study | 67 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Drug Combinations | 2 | 0.0 |
Rats | 23 | 0.0 |
Rats, Inbred BN | 2 | 4.0 |
Rats, Inbred F344 | 4 | 1.0 |
Rats, Sprague-Dawley | 8 | 0.0 |
Species Specificity | 5 | 0.0 |
Double-Blind Method | 6 | 0.0 |
Quality Control | 4 | 2.0 |
Reproducibility of Results | 8 | 0.0 |
Stroke Volume | 4 | 6.0 |
Biological Markers | 3 | 0.0 |
*Bone Density | 2 | 1.0 |
Calcium/metabolism | 2 | 0.0 |
Insulin-Like Growth Factor Binding Protein 1/blood | 2 | 10.0 |
Insulin-Like Growth Factor Binding Protein 3/blood | 2 | 3.0 |
Regression Analysis | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Sensitivity and Specificity | 10 | 0.0 |
Cell Line | 3 | 0.0 |
Conserved Sequence | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 42 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Tumor Cells, Cultured | 4 | 0.0 |
*Child Development | 2 | 6.0 |
Incidence | 2 | 0.0 |
Infant | 20 | 0.0 |
Infant, Newborn | 18 | 0.0 |
Pregnancy | 7 | 0.0 |
Energy Intake | 2 | 1.0 |
Prevalence | 6 | 0.0 |
Sex Factors | 9 | 0.0 |
Glucose/metabolism | 2 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
*Electroencephalography | 3 | 2.0 |
Infusions, Intravenous | 4 | 0.0 |
Prospective Studies | 17 | 0.0 |
Colorimetry | 2 | 3.0 |
Temperature | 2 | 0.0 |
Risk Factors | 11 | 0.0 |
Blood Glucose/metabolism | 3 | 0.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Insulin/blood | 2 | 0.0 |
Kinetics | 8 | 0.0 |
Metabolic Clearance Rate | 7 | 2.0 |
Aged, 80 and over | 24 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Myocardium/*metabolism | 2 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
*Diet | 3 | 1.0 |
Magnetic Resonance Imaging/*methods | 2 | 2.0 |
Prognosis | 7 | 0.0 |
Time Factors | 18 | 0.0 |
HIV-1/*genetics | 2 | 0.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Heart Rate | 5 | 2.0 |
Italy | 2 | 0.0 |
Systole | 3 | 3.0 |
English Abstract | 30 | 0.0 |
Radiopharmaceuticals/diagnostic use | 2 | 3.0 |
*Tomography, Emission-Computed, Single-Photon | 3 | 10.0 |
*Attitude to Health | 2 | 6.0 |
Gestational Age | 3 | 0.0 |
Questionnaires | 2 | 0.0 |
Life Tables | 2 | 1.0 |
Treatment Outcome | 7 | 0.0 |
Base Sequence | 5 | 0.0 |
Evaluation Studies | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
Body Height | 6 | 3.0 |
Drug Administration Schedule | 4 | 0.0 |
Longitudinal Studies | 7 | 0.0 |
Growth/drug effects | 2 | 13.0 |
Cross-Sectional Studies | 6 | 0.0 |
Computer Simulation | 3 | 0.0 |
*Electrocardiography | 2 | 3.0 |
Fourier Analysis | 4 | 7.0 |
Polysomnography | 2 | 4.0 |
Thermodynamics | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Electrocardiography, Ambulatory | 3 | 10.0 |
*Heart Rate | 4 | 8.0 |
Aging/*physiology | 2 | 0.0 |
Brain/enzymology | 2 | 1.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Body Mass Index | 9 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Cholesterol/blood | 8 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 5 | 0.0 |
Plasminogen Activator Inhibitor 1/*metabolism | 2 | 9.0 |
Triglycerides/blood | 9 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Mice | 18 | 0.0 |
Mutation | 2 | 0.0 |
Pedigree | 6 | 0.0 |
Ribs/*abnormalities/radiography | 2 | 66.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Spine/*abnormalities/radiography | 2 | 100.0 |
Survival Analysis | 3 | 0.0 |
Anions | 2 | 4.0 |
Neutrophils/*metabolism | 2 | 1.0 |
Enzyme Tests | 2 | 2.0 |
Follow-Up Studies | 12 | 0.0 |
Syndrome | 2 | 0.0 |
Algorithms | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Japan | 3 | 0.0 |
Linear Models | 3 | 0.0 |
Alcohol Drinking | 3 | 2.0 |
Cardiovascular Diseases/etiology | 2 | 4.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Exercise | 2 | 1.0 |
Hypercholesterolemia/blood/epidemiology | 2 | 66.0 |
Hyperlipidemia/blood/*epidemiology | 2 | 66.0 |
Lebanon/epidemiology | 2 | 20.0 |
Lipoprotein(a)/blood | 2 | 3.0 |
Lipoproteins, LDL Cholesterol/blood | 4 | 0.0 |
Smoking | 2 | 0.0 |
Electromyography | 3 | 1.0 |
Electrocardiography | 3 | 0.0 |
Multivariate Analysis | 5 | 0.0 |
Nonlinear Dynamics | 3 | 12.0 |
Magnesium/*blood | 2 | 13.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Rats, Inbred Strains | 7 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Genotype | 4 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Acute Disease | 2 | 0.0 |
Laboratories/*standards | 2 | 8.0 |
Age Distribution | 2 | 0.0 |
Netherlands/epidemiology | 2 | 1.0 |
Severity of Illness Index | 3 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Binding Sites | 2 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Wing/*embryology | 2 | 40.0 |
Smoking/adverse effects | 2 | 0.0 |
Carcinoma, Squamous Cell/*pathology | 2 | 2.0 |
Diagnosis, Differential | 6 | 0.0 |
Karyometry | 2 | 40.0 |
Observer Variation | 4 | 3.0 |
Body Weight | 6 | 0.0 |
Carrier Proteins/*blood | 3 | 1.0 |
Lipase/*blood | 2 | 3.0 |
Creatine Kinase/blood | 2 | 1.0 |
Blood Coagulation Factors/*analysis | 2 | 2.0 |
Factor IX/analysis | 2 | 28.0 |
Factor VII/analysis | 2 | 6.0 |
Factor X/analysis | 2 | 40.0 |
Phenotype | 8 | 0.0 |
Phylogeny | 2 | 0.0 |
Densitometry, X-Ray | 2 | 1.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Recurrence | 2 | 0.0 |
Evolution | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Half-Life | 4 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Cross-Over Studies | 4 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Blood Pressure | 4 | 0.0 |
Exercise/*physiology | 4 | 1.0 |
Animals, Genetically Modified | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 6 | 1.0 |
Area Under Curve | 2 | 0.0 |
Biopsy | 3 | 0.0 |
Chronic Disease | 5 | 0.0 |
Calcium/blood | 3 | 1.0 |
Antineoplastic Agents/*pharmacology | 13 | 1.0 |
Succinate Dehydrogenase/*antagonists & inhibitors | 9 | 90.0 |
Cardiac Volume | 2 | 11.0 |
Coronary Angiography | 2 | 0.0 |
Coronary Disease/*physiopathology | 2 | 11.0 |
Diastole | 2 | 2.0 |
Heart Catheterization | 2 | 3.0 |
Hemodynamic Processes | 2 | 1.0 |
Multicenter Studies | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Reaction Time | 2 | 1.0 |
Visual Acuity | 2 | 1.0 |
Psychiatric Status Rating Scales | 3 | 1.0 |
Neoplasm Staging | 6 | 0.0 |
Lipids/*blood | 3 | 0.0 |
Single-Blind Method | 2 | 0.0 |
Carcinoma, Squamous Cell/*drug therapy/enzymology | 2 | 100.0 |
Cisplatin/therapeutic use | 3 | 7.0 |
Drug Screening Assays, Antitumor/methods | 3 | 18.0 |
Fluorouracil/therapeutic use | 2 | 4.0 |
*Subrenal Capsule Assay | 2 | 40.0 |
Succinate Dehydrogenase/metabolism | 4 | 11.0 |
Echocardiography | 2 | 0.0 |
Organ Size | 2 | 1.0 |
In Vitro | 14 | 0.0 |
Blood Glucose/analysis | 2 | 0.0 |
Diabetes Mellitus, Type 1/*physiopathology | 2 | 3.0 |
Signal Processing, Computer-Assisted | 2 | 4.0 |
Exercise Test | 2 | 0.0 |
Lactic Acid | 2 | 3.0 |
Cystic Fibrosis/complications/*metabolism | 2 | 40.0 |
*Energy Metabolism | 2 | 2.0 |
Carbazilquinone/pharmacology | 2 | 100.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Doxorubicin/pharmacology | 3 | 1.0 |
Drug Screening Assays, Antitumor | 9 | 2.0 |
Flow Cytometry | 3 | 0.0 |
Mitomycin/pharmacology | 2 | 2.0 |
Reference Standards | 2 | 0.0 |
Norepinephrine/blood | 3 | 1.0 |
Leukocyte Count | 2 | 0.0 |
Administration, Oral | 5 | 0.0 |
Renal Dialysis | 2 | 0.0 |
Drug Resistance | 3 | 0.0 |
Succinate Dehydrogenase/antagonists & inhibitors | 8 | 88.0 |
Heat | 4 | 0.0 |
Glomerular Filtration Rate/physiology | 2 | 10.0 |
Cell Division | 2 | 0.0 |
*Heat | 3 | 2.0 |
Neoplasms/*pathology | 3 | 5.0 |
Stomach Neoplasms/pathology | 3 | 13.0 |
L-Selectin | 2 | 3.0 |
Mathematics | 2 | 1.0 |
Models, Anatomic | 2 | 14.0 |
Cell Survival | 2 | 0.0 |
*Hyperthermia, Induced | 3 | 6.0 |
Biological Transport | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Lymphocyte Subsets | 2 | 1.0 |
Amino Acids/analysis | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Swine | 2 | 0.0 |
Statistics | 2 | 0.0 |
Remission Induction | 2 | 0.0 |
Birth Weight | 3 | 1.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Dogs | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Mesocricetus | 2 | 1.0 |
Muscles/*metabolism | 2 | 2.0 |
Chi-Square Distribution | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Hospitals, Urban | 2 | 25.0 |
Biological Availability | 2 | 0.0 |
Carcinoma, Squamous Cell/*drug therapy | 2 | 7.0 |
Head and Neck Neoplasms/*drug therapy | 2 | 11.0 |
*Drug Screening Assays, Antitumor | 2 | 16.0 |
Colonic Neoplasms/*drug therapy | 2 | 11.0 |
Rectal Neoplasms/*drug therapy | 2 | 66.0 |
Fluorouracil/*analogs & derivatives/pharmacology | 2 | 100.0 |
Renin/*blood | 2 | 2.0 |
Injections, Intravenous | 2 | 0.0 |
Kidney/*physiopathology | 2 | 3.0 |
Renin/blood | 2 | 0.0 |
Carbazilquinone/*pharmacology | 2 | 100.0 |
Mitomycin | 3 | 6.0 |
Mitomycins/*pharmacology | 2 | 50.0 |
Pressure | 2 | 1.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Mass Screening | 2 | 1.0 |
Survival Rate | 3 | 0.0 |
Drug Screening Assays, Antitumor/*methods | 2 | 66.0 |
Antibody Specificity | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Evoked Potentials | 2 | 3.0 |
Social Isolation | 2 | 9.0 |
Alleles | 2 | 0.0 |
Gene Frequency | 3 | 0.0 |
Injections, Subcutaneous | 2 | 0.0 |
Mitomycins/pharmacology | 2 | 6.0 |
Hydrocortisone/blood | 2 | 0.0 |
Probability | 2 | 0.0 |
Rats, Inbred SHR | 2 | 2.0 |
Rats, Inbred WKY | 2 | 2.0 |
Colony-Forming Units Assay/*methods | 2 | 33.0 |
Succinate Dehydrogenase/*diagnostic use | 2 | 100.0 |
Tumor Stem Cell Assay/*methods | 2 | 33.0 |
Infusions, Parenteral | 2 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Canada | 2 | 1.0 |
Long-Term Care | 2 | 3.0 |
Models, Biological | 3 | 0.0 |
Lymphocytes/*immunology | 3 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 4 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Cytotoxicity Tests, Immunologic | 4 | 0.0 |
*Epitopes | 3 | 2.0 |
*HLA Antigens | 4 | 1.0 |
Haploidy | 2 | 1.0 |
*Histocompatibility Antigens | 4 | 5.0 |
Histocompatibility Testing | 2 | 0.0 |
